Contact Peeyush Shrivastava
Title CEO


CardioFlux is a medical device capable of passively, and without patient contact, measuring the cardiac generated magnetic fields emanating from a patient’s chest. These signals have been shown to be highly sensitive to a broad spectrum of cardiovascular diseases, including ischemia and arrhythmia. This technology can be wheeled to the bedside of the emergency room, and poses no risk to the patient (i.e. no radiation, injections). The sensitivity and specificity of the system to ischemia in patients with unstable angina has been demonstrated to be comparable to stress imaging, yet can be performed in seconds and without patient risk.

Company News

Genetesis Announces New Scientific Advisory Board

DateAug 26, 2021
Genetesis, the market leader in the design, development and commercialization of biomagnetic imaging solutions, today announced its new Scientific Advisory Board (SAB).
Read More →

FDA Awards Genetesis Breakthrough Device Designation for CardioFlux® Imaging Technology

DateDec 15, 2020
CardioFlux®, the most advanced commercially available magnetocardiograph (MCG), leverages highly sensitive room temperature magnetometers to deliver noninvasive measurement of the heart’s naturally-generated magnetic fields.
Read More →

Genetesis lands strategic investment to close $9.2M Series B

DateMay 8, 2020
Genetesis Inc, a medical technology company that has developed non-invasive, biomagnetic CardioFluxTM imaging, today announced several important updates. The company has closed significant strategic investments from TDK Ventures and an undisclosed Fortune 500 global, healthcare company, completing a $9.2M Series B financing. The round included participation by return investors CincyTech, Ohio Innovation Fund and Mark Cuban.
Read More →

TDK Ventures Invests in Biomagnetic Medical Imaging Company Genetesis

DateApr 21, 2020
“TDK’s rich history in magnetics and its recent breakthroughs in biomagnetics at picoTesla levels makes them one of our strongest partners to date,” said Peeyush Shrivastava, CEO and founder of Genetesis. “We are committed to bring the most accurate diagnostics that can assist emergency physicians and cardiologists in making the best decisions for cardiac health in a non-invasive and rapid fashion. We are elated to have TDK as our strategic partner because of their pioneering work in magnetic materials and its commercialization. Their recent leadership around supporting frontier-tech entrepreneurs caught our attention and we are excited about this next chapter.”
Read More →